drugset
drugset / Trial / NCT04403555

Ivermectin as a Novel Therapy in COVID-19 Treatment

NCT04403555 ↗

Phase 2/3 Completed 164 enrolled Tanta University
RandomizedParallel-groupOpen-labelTreatment

Summary

Efficacy of Ivermectin in COVID-19 treatment

Timeline

Start
2020-06-01
Primary completion
2020-10-31
Completion
2020-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivermectin Small molecule 12 mg —

Indications

COVID-19